Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple myeloma; however, most patients have a relapse. Frontline lenalidomide therapy has increased the number of patients with lenalidomide-refractory disease at the time of the first relapse. METHODS: In this phase 3, randomized, open-label trial, we evaluated belantamab mafodotin, pomalidomide, and dexamethasone (BPd), as compared with pomalidomide, bortezomib, and dexamethasone (PVd), in lenalidomide-exposed patients who had relapsed or refractory myeloma after at least one line of therapy. The primary end point was progression-free survival. Disease response and safety were also assessed. RESULTS: A total of 302 patients underwent randomization; 155 were assigned to the BPd group, and 147 to the PVd group. At a median follow-up of 21.8 months (range, <0.1 to 39.2), the 12-month estimated progression-free survival with BPd was 71% (95% confidence interval [CI], 63 to 78), as compared with 51% (95% CI, 42 to 60) with PVd (hazard ratio for disease progression or death, 0.52; 95% CI, 0.37 to 0.73; P<0.001). Data on overall survival were immature. The percentage of patients with a response to treatment (partial response or better) was 77% (95% CI, 70 to 84) in the BPd group and 72% (95% CI, 64 to 79) in the PVd group; 40% (95% CI, 32 to 48) and 16% (95% CI, 11 to 23), respectively, had a complete response or better. Grade 3 or higher adverse events occurred in 94% of the patients in the BPd group and 76% of those in the PVd group. Ocular events occurred in 89% of the patients who received BPd (grade 3 or 4 in 43%) and 30% of those who received PVd (grade 3 or 4 in 2%); ocular events in the BPd group were managed with belantamab mafodotin dose modification. Ocular events led to treatment discontinuation in 9% of the patients in the BPd group and in no patients in the PVd group. CONCLUSIONS: Among lenalidomide-exposed patients with relapsed or refractory myeloma, BPd conferred a significantly greater benefit than PVd with respect to progression-free survival, as well as deeper, more durable responses. Ocular events were common but were controllable by belantamab mafodotin dose modification. (Funded by GSK; DREAMM-8 ClinicalTrials.gov number, NCT04484623; EudraCT number, 2018-004354-21.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two recent phase III studies have shown significant benefit with belantamab (Table 9), and hence it is likely the drug will be reapproved in the near future with better recommendations for dosing and dose frequency.162,163”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [163]
In the citing paper
“The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [26]
In the citing paper
“Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular toxicity, regular ophthalmic monitoring, dose modifications, and supportive care can inform management decisions.26,28”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [26]
In the citing paper
“Belantamab mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM.26,27”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [26]
Citations
Cites
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827
Self-citationIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Ribas de Almeida, A. C., Hajek, R., Kim, K., Grosicki, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405090 · Cited by 199
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A., Callander, N., Sborov, D., Suvannasankha, A., et al. (2021) · Cancer · doi:10.1002/cncr.33809 · Cited by 144
Self-citationLonial, S., Nooka, A. K., Thulasi, P., Badros, A. Z., Jeng, B. H., Callander, N. S., Potter, H. A., Sborov, D., Zaugg, B. E., Popat, R., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00494-4 · Cited by 89
Self-citationNavigating the treatment landscape in multiple myeloma: which combinations to use and when?
Goldschmidt, H., Ashcroft, J., Szabo, Z., & Garderet, L. (2019) · Annals of Hematology · doi:10.1007/s00277-018-3546-8 · Cited by 79
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Moreau, P., Zamagni, E., & Mateos, M.-V. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0200-1 · Cited by 68
Self-citationCurrent Treatment Strategies for Multiple Myeloma
Branagan, A. R., Lei, M. M., Lou, U. Y., & Raje, N. S. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00244 · Cited by 60
Cited by
Items 101–189 of 189
Popat, R., Augustson, B. M., Cannell, P., Stockerl-Goldstein, K. E., Spencer, A. G., Khot, A. S., Nooka, A. K., Patel, N., Kasinathan, R. S., McKeown, A., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3216 · Cited by 2
“Belantamab mafodotin has shown clinical benefit in combination regimens for RRMM (9, 10).”
Self-citationNewman, C., Taylor, C., Sohanpal, G., Högg, T., Kennedy, J., McKinley, E. T., Koudouna, E., Sayers, E. J., Jones, A. T., Watson, P., et al. (2026) · Cell Biology and Toxicology · doi:10.1007/s10565-026-10183-2 · Cited by 2
“Belantamab mafodotin has been evaluated as a monotherapy and in combination regimens in relapsed/refractory MM (RRMM) and is under investigation for other indications (ClinicalTrials. gov 2023; ClinicalTrials.gov 2024; Dimopoulos et al. 2024, 2023; Hungria et al. 2024).”
Iimura, Y., Sakai, H., Nakajima, I., Kuroda, S., Nakamura, M., & JASCC Onco Ophthalmology Working Group (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03096-x · Cited by 1
“[60].”
Peck, O. H., McCoubrey, A., Snowden, J. A., Wechalekar, A. D., Travers, J., Lees, J. S., Petrie, M. C., & Lang, N. N. (2026) · Open Heart · doi:10.1136/openhrt-2026-004240 · Cited by 1
Lonial, S., Dimopoulos, M. A., Γαβριατοπούλου, Μ., Kim, K., Min, C.-K., Oriol, A., Moreira, C. C. C., Quach, H., Qiu, L., Xia, Z., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00450-x · Cited by 1
Self-citationKapur, R., McCarron, J., Rajeeve, S., & Mohyuddin, G. R. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2411625 · Cited by 1
“CArtitUde-4 [5] and dreAMM-8 [6] have also included heavily pre-treated patients, although these trials were not limited to the triple-class refractory space.”
Multi-Omic Profiling Reveals Epigenetic Drivers of Immunotherapy Resistance in Multiple MyelomaPreprint
Haertle, L., Buenache, N., González, F. J. V., Díaz, I. E., del Campo, P. L., Rosa-Rosa, J. M., Fernández, R. A. A., Muñoz, M. N. L., Sánchez‐Pina, J. M., García-Ortiz, A., et al. (2025) · medRxiv · doi:10.1101/2025.04.15.25325788 · Cited by 2
“Before undergoing BLMF treatment, this patient had undergone six cycles of Rd in the third line and Pd in the seventh line ( SI Figure 1 ).”
InfluentialMatsumura, N., & Mandai, M. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02811-4 · Cited by 1
Hu, X., Zhang, Q., Wang, L., Zhang, J., Ouyang, Q., Wang, X., Li, W., Xie, W., Tong, Z., Wang, S., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4889525
Treatment of Early Relapse: Non-CAR T Cells
Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(24)00361-6
Self-citationHow to rescue a DreaMM deferred …
Joseph, N. S., & Lonial, S. (2024) · Med · doi:10.1016/j.medj.2024.07.027
Kumar, A. D., Chung, A., Pan, D., & Chari, A. (2024) · The Hematologist · doi:10.1182/hem.v21.6.202467
Sunami, K., Iida, S., Tsukada, N., Fujii, T., Kato, H., Fukushima, R., Wakabayashi, S., Nakano, H., Roy–Ghanta, S., & Kremer, B. E. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03889-8
Self-citationPhua, C. W. T., & McCulloch, S. (2025) · Canadian Hematology Today · doi:10.58931/cht.2025.4s0161
Therapie des multiplen Myeloms – was ist neu und was bleibt?
Kortüm, K. M., Waldschmidt, J. M., & Einsele, H. (2025) · Die Onkologie · doi:10.1007/s00761-024-01675-z
Neue Möglichkeiten für die Rezidivtherapie
Hentrich, M., Mertens, L., & Högner, M. (2025) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-025-0954-5
Luna, J., d'Estrube, T., Jacobsen, A., Lehne, M., Wellmann-Pichler, B., Mevius, A., & Dornig, S. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06427-6
Hematological Treatments and Disease Modifying Therapies in AL Cardiac Amyloidosis
Lebel, E., Even‐Zohar, N. G., & Gatt, M. E. (2025) · Springer eBooks · doi:10.1007/978-3-031-88342-2_14
Tumultuous Development of Venetoclax in t(11;14) Multiple Myeloma
Kaiser, M., & Cliff, E. R. S. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01088
Gay, F., Marchetti, E., & Bertuglia, G. (2025) · Kompass Onkologie · doi:10.1159/000547999
Multiples Myelom: Hochrisikomyelom Therapiestrategien und neue Ansätze
Artzenroth, C., Al-Bazaz, M., Kosch, R., Schaefers, C., Weisel, K. C., & Leypoldt, L. B. (2025) · Trillium Krebsmedizin · doi:10.47184/tk.2025.05.2
EHA 2025 - Viel Neues in der Hämatoonkologie
Kretzschmar, A. (2025) · Onkologische Welt · doi:10.1055/a-2681-4741
Belantamab mafodotin for the treatment of multiple myeloma
Oriol, A., Ibarra, G., Loscos, J., & Abril, L. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2576502
“At time of publication, none of the arms had reached the median PFS, 12-month PFS was 71% for BPd and 51% for (HR 0.52; p < 0.001) [46].”
InfluentialGehlert, C. L., Schewe, D. M., Klausz, K., Krohn, S., Winterberg, D., Vogiatzi, F., Boje, A. S., Baum, N., Könecke, M., Lux, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.30.684608
Mainou, M., Alsadhan, M., Tsapa, K., Visram, A., Mian, H. S., Popat, R., Mai, E. K., Chakraborty, R., Hadidi, S. A., Mohan, M., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf326
“41,42 In addition, some standard care regimens are now performing better than their historical pivotal trials, potentially due to better supportive care and improved performance status and organ function of patients due to more effective prior treatments.”
Dreaming of a better future: drug development in myeloma
Parikh, R., & Lonial, S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015740
Shustik, J. (2025) · Canadian Hematology Today · doi:10.58931/cht.2025.4379
Sunami, K., Handa, H., Ichii, M., Ikezoe, T., Suzuki, K., Yamaguchi, Y., Yonekawa, T., Endo, A., Nakano, H., Lewis, E., et al. (2026) · International Journal of Hematology · doi:10.1007/s12185-025-04150-6
“The methodology of the DREAMM-8 study has been previously reported [16].”
InfluentialSelf-citationKosch, R., Yousefi, B., Laubach, N. C., Truger, M. S., Haferlach, T., Gersting, S. W., Teipel, R., Sonnemann, P., Al-Bazaz, M., Artzenroth, J. C., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8568919/v1
Mansour, R. A., Green, K. M., Graf, C., Chang, M., Magee, G., Davis, J. A., Zayad, A., Ahmed, N., Mushtaq, M. U., Ouchveridze, E., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70077
“[34].”
Availability of pharmacological treatments for multiple myeloma in Spain
Garrido‐Alejos, G., Feliu, A., Gay-Pérez, D., Pontes, C., & Vallano, A. (2026) · The European Journal of Health Economics · doi:10.1007/s10198-025-01883-3
Arakawa, Y., Taniyama, D., Suzuki, K., Yano, S., & Pommier, Y. G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.06.704297
“While current anti-BCMA ADCs utilize microtubule inhibitor payloads (46,47), TOP1 payloads such as exatecan could offer superior efficacy in SLFN11-high MM patients, particularly at relapse where both SLFN11 expression and proliferative activity are high.”
Self-citationKang, Y., Liu, Q., Liu, Q., Xie, W., Sun, C., & Mei, H. (2026) · Blood Cancer Journal · doi:10.21203/rs.3.rs-8750940/v1
When Outcomes With Bispecifics Start to Resemble CAR T Cells: Lessons From MajesTEC-3
Pan, D., Kumar, A., Lipof, J. J., Chung, A., & Chari, A. (2026) · The Hematologist · doi:10.1182/hem.v23.2.202624
Liu, Y., Lee, J. H., Mo, C. C., Salman, T. J., Hossain, S., Midha, S., Nadeem, O., Nicholson, T., Croteau, J., Kazierad, N., et al. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2646947 · Cited by 3
“…(Pom-Vd) in a similar patient population to that enrolled in DREAMM-7 and similarly demonstrated a highly significant PFS benefit [218,229,230,252]; median PFS was 32.6 versus 12.5 months with Bela-Pom-dex versus Pom-Vd (HR 0.49) [218], with benefit consistently seen in patients…”
InfluentialChoosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection
Hadidi, S. A., Costello, C. L., Costa, L. J., Dhakal, B., Georges, P., Gajra, A., Lin, Y., Bhargava, R. S., Paner-Straseviciute, A., & Vij, R. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.009 · Cited by 1
Richter, J. R., Davis, M., & Chai, Y. (2026) · The Oncologist · doi:10.1093/oncolo/oyag112
Corradini, P., Musto, P., Galeone, C., Mariani, P., Resci, F., & Cavo, M. (2026) · Leukemia Research · doi:10.1016/j.leukres.2026.108230
Self-citationMatsumoto, J., Takeda, T., Sugimoto, S., Sakai, T., Loyao, B. B., Higashionna, T., Hamano, H., See, G. L., Ariyoshi, N., & Zamami, Y. (2026) · Leukemia Research · doi:10.1016/j.leukres.2026.108236
Can Belantamab mafodotin cause macro LDH?
Hakakian, L., Shragai, T., Trestman, S., Cohen, Y. C., Katz, B., Arafat, N., Hassoun, E., Melamed, N., & Avivi, I. M. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2649877
“…pomalidomide and dexamethasone (Pd) in earlier stages, including patients who have failed at least one line of treatment, demonstrated highly encouraging results, achieving a 12-month progression-free survival (PFS) rate of 71%, compared to 51% in patients who received bortezomib (V) and Pd [6].”
Advances in the Treatment of Multiple Myeloma
余, 佳. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641697
Case Report: Corneal Toxicity in Antibody-Drug Conjugate
Skoog, W. (2025) · Clinical Insights in Eyecare · doi:10.66574/001c.142745
Ocular side effects of antibody–drug conjugates for cancer treatment
Heitz, F., Scheider, A., Harter, P., & Groeben, M. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2026.0060
Li, H., Xia, Q., Yu, M., Lv, Y., Xiao, J., Guo, X., Dong, K., Zhou, Y., Zhong, L., Wang, T., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3227-0
“In this review, we summarize the achievements of recent years regarding combination therapy regimens that incorporate mAbs for treating MM (Table 2) (Alhallak et al., 2021; Facon et al., 2024; Mai et al., 2024; Ocio et al., 2023; Pour et al., 2024; Spencer et al., 2024).”
Antibody-Drug Conjugates in Oncology: Mechanisms, Clinical Progress, and Future Directions
Zhu, Z., Wang, S., Hong, W., Zhong, Q., Wang, W., Wang, N., Bai, M., & Ji, Z. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i2.32
Chen, X., Hakim, S., Lien, Y. T., Dimopoulos, M. A., Lichtman, E. I., Min, C., Chng, W. J., Ailawadhi, S., Delimpasi, S., Hrabrick, E., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.05.009
Self-citationZhou, C.-Q., Zhou, S.-Q., & Ke, Q.-H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1811170
“The static control arm (PVd/DPd), while appropriate at design, may magnify cilta-cel ’ s bene fi t relative to newer regimens, underscoring the need for head-to-head trials against contemporary standards (3 – 5).”
Clinical implications of minimal residual disease monitoring in multiple myeloma
Yoroidaka, T. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04229-8
“[54].”
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
Morgan, G. J., Lee, D. D., Joseph, N. S., Lonial, S., Rodríguez‐Otero, P., & San-Miguel, J. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517494
Redefining Early Relapse in Multiple Myeloma — Time to Change the Rules
Mateos, M. (2026) · New England Journal of Medicine · doi:10.1056/nejme2605404
Self-citationAntibody–drug conjugates in hematologic malignancies
Patel, K., Strickland, S. A., & Lee, H. C. (2026) · Cancer · doi:10.1002/cncr.70421 · Cited by 1
“95,96,101,102,106–111”
InfluentialHansen, D. K., Mateos, M., & Costa, L. J. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019699
“20,21,31,98 Selected physiologically robust patients with adequate caregiver support may be candidates for CAR-T therapy, particularly when patients prioritize a time-limited therapy and accept the toxicity profile of this treatment.”
Self-citationCarreño, F. O., van Noort, M., Taylor, A. B., Zeiser, S., Papathanasiou, T., Post, T. M., Lien, Y. T., Ho, Y. L., & Ferron‐Brady, G. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70276 · Cited by 1
“[8, 11, 13, 14] (Table S1).”
Bertuglia, G., Nicola, A. D., Gay, F., Larocca, A., Bruno, B., & D’Agostino, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1822419
“In contrast, in DREAMM-8, all patients had prior lenalidomide exposure (81% were refractory), but only ~20% were exposed or refractory to daratumumab (12).”
InfluentialInnate immune dysregulation in multiple myeloma: molecular basis and mechanistic interventions
Wang, G., Gao, H., Xie, T., & Zi, F. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116996
Mina, R., Terpos, E., Cani, L., Nooka, A. K., Trudel, S., Voorhees, P., Mian, H. S., Dhakal, B., Usmani, S. Z., Richter, J., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.06.014
Self-citationDesign, Synthesis, and Antitumor Activity of Benzodioxolane-Conjugated Pomalidomide Derivatives
Wang, X., Wang, M., Sun, Y., Wang, H.-N., Wang, Y., Ji, J., & Zhao, Y. (2026) · Russian Journal of Organic Chemistry · doi:10.1134/s1070428025604200
Practical recommendations for infectious prophylaxis and vaccination in multiple myeloma patients
Bergantim, R., Roque, A. I., Jorge, A., Freitas, J. G., Miranda, M. T., Nunes, M., Ionita, A., Bernardo, P. V., Vieira, J., Aguiar, E. V., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1847793 · Cited by 1
“In the DREAMM-7 and DREAMM-8 trials, infections remained among the most frequent adverse events, with pneumonia as the predominant severe infection, and opportunistic infections remained uncommon (51, 52).”
Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma
Worth, H. A., & Costa, L. J. (2026) · Cancer · doi:10.1002/cncr.70519
“24 Although BsAb, CAR T cells, and antibody - drug conjugate–based triplets appear to deliver improved efficacy over legacy regimens, they have unique challenges regarding toxicity, access and afford-ability.”
Periplocin targets STAT3 to suppress MYC expression and inhibit multiple myeloma cell proliferation
Wei, R.-F., Chen, J., Lai, S.-P., Chen, Z.-A., Zhou, Y.-Y., Liao, Y.-P., & Chen, Y. (2026) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2026.07.002
Podvin, B., Lee, H., Tilmont, R., Decool, G., Cavalieri, D., Demarquette, H., Gower, N., Nudel, M., Bourgeois, E., Robu, D., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020518
Elranatamab: A novel B-cell maturation T-cell engager
Hossain, S., & Bianchi, G. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2694852
Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma
Samuel, M., Flores, M. S., Lowy, J. A., Rogers, M. F., Avigan, Z. M., Rattu, M. A., & Richter, J. R. (2026) · Future Oncology · doi:10.1080/14796694.2026.2700028 · Cited by 1
Arakawa, Y., Taniyama, D., Suzuki, K., Yano, S., & Pommier, Y. G. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-26-0162
“Whereas current anti-BCMA ADCs utilize microtubule inhibitor payloads (55, 56), TOP1 payloads such as deruxtecan and exatecan could offer superior efficacy in SLFN11 -high patients with multiple myeloma, particularly at relapse where both SLFN11 expression and proliferative activity are high.”
Self-citationPotential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma
Sra, M. S., & Kumar, S. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2703858
“DREAMM-8, which compared belantamab with pomalidomide and dexamethasone (BPd) versus bortezomib/pomalidomide/dexamethasone (PVd), reported a median PFS of 32.6 versus 12.5 months with a hazard ration of 0.49 [56].”
InfluentialRevolutionizing 2L+ Myeloma: A Podcast on the New Era of BCMA-Targeted Bispecific Antibody Therapies
Mina, R., Doyle, M., & Nooka, A. K. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03715-z
Shivarov, V. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30050-9.00021-7
More options, more questions in the management of early relapsed and/or refractory multiple myeloma
Tan, C. R., & Mailankody, S. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01191-6
Podar, K. (2026) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-026-01121-3
Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies
Mathias, F., Fersing, C., Bourgarel‐Rey, V., Gabert, J. A., & Peyron, F. (2026) · Cells · doi:10.3390/cells15161439
“Belantamab mafodotin was later approved in China in 2026 [182,183].”
Trudel, S., Beksaç, M., Pour, L., Delimpasi, S., & Vorob, V. (2026) · NCODA Oncology and Hematology Meeting Abstracts · doi:10.67209/kthg9812
Self-citation2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group
Beksaç, M., Mastanzade, M. G., Değirmenci, B. B., Oluk, B., Sağlam, B., Özlük, D. Ö., Cengiz, E., Alhan, F. N., Dikici, H. Z., Uygun, K. Y., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.08.008 · Cited by 1
Barilà, G., Grassi, A., Ruocco, V., Liberatore, C., Olivari, E., Tinelli, M., Fazio, F., Morè, S., Favero, E., Cartia, C. S., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70751
Multiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 5
Su, S., Yan, S., Wu, J., & Xiao, Y. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11228-z
Treatment Decisions in Multiple Myeloma
Mouhieddine, T. H., & Anderson, K. C. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2605253 · Cited by 1
Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making
Bazarbachi, A. H., Lentzsch, S., Facon, T. T. F., Harousseau, J., & Mohty, M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00545
Ahrens, R., Yousefi, B., Laubach, N. C., Truger, M. S., Haferlach, T., Heins, S., Teipel, R., Mitsiades, C. S., Papadopoulos, E., Ahrens, K., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.010
Schaefers, C., Khandanpour, C., Hänel, M., Kull, M., Alsdorf, W. H., Kamili, A., Kosch, R., Krüger, W., Bohl, S., Mai, E. K., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-16905-3
“…(BVd; median (m) PFS 36.6 months) over daratumumab plus bortezomib and dexamethasone (DVd; mPFS 13.4 months), including an OS benefit [21], and in combination with pomalido-mide and dexamethasone (BPd, mPFS not reached) over pomalidomide, bortezomib, and dexamethasone (PVd, mPFS 12.7 months) [22].”
InfluentialIdentification of broadly tumour-reactive γδ TCRs from multiple myeloma
Paul, M. S., Hendrikse, L. D., Ying, F., Snow, B. E., Luo, P., Helke, S., Smith, L. K., Hilal, A., Abelman, D. D., Ramamurthy, N., et al. (2026) · Nature · doi:10.1038/s41586-026-11055-9
Self-citationNtanasis‐Stathopoulos, I., Terpos, E., & Dimopoulos, M. A. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000845
Self-citationTailoring Therapy for Frail and Elderly Myeloma Patients
George, T., & Szalat, R. E. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000850
Myélome multiple en 2026 : stratégies thérapeutiques en situation de rechute
Debureaux, P.-É., Cazaubiel, T., Chalopin, T., & Talbot, A. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.07.008
Clements, J. D., Sorribes, I. C., Kaullen, J. D., Neumar, C., Taylor, A. B., Yue, M. S., Chen, X., Struemper, H., & Ferron‐Brady, G. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70337
Martino, M. V., Bilardi, E., Pitea, M., Porto, G., Policastro, G., Utano, G., Giordano, L., Santoro, G., Germanò, J., & Alati, C. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70328
Hays, P. V. (2026) · Discover Medicine · doi:10.1007/s44337-026-00721-6
“” [8].”
Mustafa, Y. F. (2026) · Seminars in Oncology · doi:10.1016/j.seminoncol.2026.152568
Dimopoulos, M. A., Hungria, V., Meng, H., Radinoff, A., Li, J., Delimpasi, S., Niu, T., Mikala, G., Masszi, T., Capra, M., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01646-0
“Aligning with adaptive immunity involvement, deep and durable responses are a hallmark of belantamab mafodotin treatment (observed with monotherapy and combination regimens), and led to improved PFS over time in this study [10 – 13].”
Self-citationCorneal Toxicity From Antibody–Drug Conjugates in Fuchs Corneal Dystrophy
Dhallan, A., Nguyen, J., & Thulasi, P. (2026) · Cornea Open · doi:10.1097/coa.0000000000000084
Metadata
- Authors
- Dimopoulos, M. A., Beksac, M., Pour, L., Delimpasi, S., Vorobyev, V., Quach, H., Spicka, I., Radocha, J., Robak, P., Kim, K., Cavo, M., Suzuki, K., Morris, K., Pompilus, F., Phillips-Jones, A., Zhou, X. L., Fulci, G., Sule, N., Kremer, B. E., Opalinska, J., Mateos, M.-V., & Trudel, S.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- From the Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens (M.A.D.), and General Hospital Evangelismos (S.D.) — both in Athens; the Department of Hematology, Ankara Liv Hospital, Istinye University, Ankara, Turkey (M.B.); the Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno (L.P.), the First Faculty of Medicine, Charles University, and General Hospital, Prague (I.S.), and the Fourth Department of Internal Medicine–Hematology, University Hospital Hradec Králové, and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové (J.R.) — all in the Czech Republic; Leningrad Regional Clinical Hospital, Saint Petersburg, Russia (V.V.); the University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC, Australia (H.Q.); Medical University of Lodz, Łódź, Poland (P.R.); Sungkyunkwan University and Samsung Medical Center, Seoul, South Korea (K.K.); IRCCS Azienda Ospedaliero–Universitaria di Bologna, Seràgnol...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-08
- Volume
- 391
- Issue
- 5
- Pages
- 408-421
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399275686
- Cited by
- 189
- References
- 17
- Citations by year
- 2026: 79 · 2025: 86 · 2024: 24
- FWCI
- 58.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- belantamab mafodotin, pomalidomide, dexamethasone, relapsed/refractory multiple myeloma, lenalidomide-refractory disease, anti-CD38 monoclonal antibody, bortezomib, progression-free survival, ocular adverse effects, triplet therapy, immunomodulators, proteasome inhibitors
- MeSH terms
- Bortezomib, Lenalidomide, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Eye Diseases, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, Thalidomide, Treatment Outcome, Disease Progression, Drug Resistance, Neoplasm, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.